A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs BIIB-092 (Primary)
  • Indications Progressive supranuclear palsy
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PASSPORT
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 03 Nov 2017 Planned primary completion date changed from 22 Apr 2019 to 8 Nov 2019.
    • 02 May 2017 Status changed from not yet recruiting to recruiting.
    • 20 Apr 2017 Planned initiation date changed from 30 Mar 2017 to 26 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top